Format

Send to

Choose Destination
See comment in PubMed Commons below
Best Pract Res Clin Gastroenterol. 2012 Dec;26(6):833-41. doi: 10.1016/j.bpg.2013.01.001.

Biotherapies for GEP-NETs.

Author information

1
Dept. of Endocrine Oncology, University Hospital, Uppsala, Sweden. kjell.oberg@medsci.uu.se

Abstract

Biological treatment for GI neuroendocrine tumours (NETs) includes treatment with somatostatin analogues and alpha interferons. Both of these therapies were developed in the early 1980's and initially for treatment of a carcinoid syndrome in patients with small intestinal NETs. Later on tumour biology studies indicated that well differentiated NETs (G1-tumours) benefit from treatment with somatostatin analogues and alpha interferons. Both agents give symptomatic improvement in patients with functioning tumours in 40-60% of the patients, biochemical responses in 50-70% of the patients and significant tumour shrinkage in 5-10% of the patients. Combination therapy with somatostatin analogues and alpha interferon has demonstrated some clinical benefit.

IN CONCLUSION:

Somatostatin analogues and alpha interferons are still playing an important role and considered to be first-line treatment in functioning and in non-functioning well-differentiated NETs, (G1-tumours) and somatostatin analogues might also be applied to control clinical symptoms in G2-tumours with higher proliferation.

PMID:
23582922
DOI:
10.1016/j.bpg.2013.01.001
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center